生物制剂时代溃疡性结肠炎的手术治疗

Surgery for ulcerative colitis in the era of biological agents therapy

溃疡性结肠炎是一种病因尚不十分明确的直肠和结肠慢性非特异性炎症性疾病。英夫利昔单克隆抗体（IFX）是一种肿瘤坏死因子抗体，已被美国食品药品监督管理局批准用于治疗溃疡性结肠炎，并可诱导受损的肠黏膜愈合。全结直肠切除回肠贮袋肛管吻合术目前是溃疡性结肠炎患者手术治疗的标准手术方式。在IFX越来越被广泛应用的时代，围术期IFX的应用、手术时机及手术方式的选择，是关乎术后患者预后的重要因素。

Ulcerative colitis is an inflammatory disease of colon and rectum whose etiology is still unclear. Infliximab is an anti-tumor necrosis factor antibody, which has been approved recently by the United States FDA for the treatment of ulcerative colitis to reduce signs and symptoms, to induce clinical remission and healing of the intestinal mucosa. Total proctocolectomy with pouch-anal anastomosis are the standard operation for ulcerative colitis now. The perioperative infliximab use, operation timing and procedures are the important factors affecting prognosis of patients in the era of infliximab therapy.